Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring long-term treatment. Crisaborole significantly improved global AD signs and symptoms in 28-day phase 3 studies of patients aged ≥ 2 years with mild-to-moderate AD (Investigator’s Static Global Assessment [ISG...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Bob, Hebert, Adelaide A., Takiya, Liza, Miller, Lauren, Werth, John L., Zang, Chuanbo, Sanders, Paul, Lebwohl, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484488/
https://www.ncbi.nlm.nih.gov/pubmed/34379285
http://dx.doi.org/10.1007/s13555-021-00584-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484488/
https://www.ncbi.nlm.nih.gov/pubmed/34379285
http://dx.doi.org/10.1007/s13555-021-00584-y

Ejemplares similares